YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
BridgeBio Pharma BBIO announced that the FDA accepted its regulatory filing seeking approval for the investigational oral drug infigratinib to treat children with achondroplasia, the most common form of dwarfism. The agency has granted the…
BridgeBio Pharma, Inc. PALO ALTO, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines f…
BridgeBio Pharma, Inc. PALO ALTO, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines f…
October 6 YouTube premiere featuring Sway Calloway, Howard "H" White and leading medical and cultural voices anchors community education nationwide PALO ALTO, Calif., Oct. 6, 2026 /PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the…
BridgeBio Pharma, Inc. - Accepted for Priority Review with a PDUFA target action date of February 4, 2027; being granted Priority Review by the FDA underscores the significant unmet need for an oral targeted therapeutic option for children…
BridgeBio Pharma, Inc. - October 6 YouTube premiere featuring Sway Calloway, Howard "H" White and leading medical and cultural voices anchors community education nationwide PALO ALTO, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pha…
BridgeBio Pharma, Inc. - In exploratory analyses at Month 12, among individuals with LGMD2I/R9 (FKRP-related) with elevated HS troponin I at baseline, 100% treated with BBP-418 returned to the normal range by Month 12 versus 40% in the pla…
Investing.com -- Jefferies identified three biotechnology stocks that appear undervalued with strong commercial prospects despite a challenging macro environment. The firm noted that rising interest rates are pressuring small and mid-cap b…
Earlier this week, BridgeBio Pharma reported peer-reviewed real-world data in Cardiology and Therapy showing that its ATTR cardiomyopathy therapy acoramidis was associated with lower early clinical worsening risk versus tafamidis in newly…
BridgeBio Pharma has delivered a strong share price run in recent years, and that kind of move naturally raises the question of whether the current valuation still lines up with the sales that sit behind the story. With fresh real world da…
Friday, September 25, 2026 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including ExxonMobil Holdings Corp. (XOM), Automatic Data P…
BridgeBio Pharma, Inc. - In the first peer-reviewed, real-world, contemporary, comparative effectiveness study of TTR stabilizers in ATTR-CM using U.S. claims data, acoramidis was associated with a statistically and clinically significant…
BridgeBio Pharma, Inc. PALO ALTO, Calif., Sept. 18, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a biopharmaceutical company focused on developing medicines for genetic conditions, today an…
BioMarin Pharmaceutical BMRN announced that it is discontinuing the development of Voxzogo (vosoritide) for children with Noonan syndrome, a rare genetic condition that can affect growth and development in multiple parts of the body. This…
A month has gone by since the last earnings report for BridgeBio Pharma (BBIO). Shares have lost about 10.7% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release,…
BridgeBio Pharma, Inc. - Treatment with oral infigratinib for 52 weeks in PROPEL 3 resulted in favorable trends against placebo in clinically meaningful exploratory endpoints including sleep apnea and otitis media events Stabilization of s…
Wall Street's major market averages finished lower on Friday after traders and investors digested the latest jobs data, which came in stronger than forecasted. The blue-chip Dow ended 0.5% lower, the benchmark S&P 500 slipped 0.3%, and the…
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is asking investors to look beyond disease stabilization in transthyretin amyloid cardiomyopathy, or ATTR-CM. New cardiac magnetic resonance imaging data from the Phase 3 ATTRibute-CM study and its open…
For BioMarin Pharmaceutical BMRN, the FDA approval of Ascendis Pharma's ASND Yuviwel in February had created a problem — a new entrant targeting the same achondroplasia market as Voxzogo, its key revenue driver. But a recent settlement bet…
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. President Donald Trump has secured new drug pricing agreements with nine pharmaceutical companies, with an aim to align the prices of drug…
BridgeBio Pharma, Inc. PALO ALTO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines…
BridgeBio Pharma (NasdaqGS:BBIO) has entered a voluntary agreement with the U.S. government to expand access to its medicines and lower drug costs for American patients. The arrangement widens Medicaid access through a unique pricing and r…
On Monday, President Trump announced that his administration has signed separate drug-pricing agreements with nine mid-sized pharmaceutical companies to lower drug prices in the country. These companies include Alcon, Astellas Pharma ALPMY…
Rare diseases have moved steadily from being an overlooked corner of medicine to an important frontier for drug innovation. The FDA estimates that more than 7,000 rare diseases affect more than 30 million Americans, while most of these con…
BridgeBio Pharma, Inc. PALO ALTO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines…
[New York City and London multiple exposure image] Stock index futures pointed to a weaker open on Tuesday, setting Wall Street up for a lower start to September as investors monitored renewed tensions in the Middle East. Here are the five…
[Inspecting capsules before production] Dejan Sarec/iStock via Getty Images U.S. President Donald Trump introduced a new set of drug-pricing deals with global pharmaceutical companies and smaller biotechs on Monday, advancing efforts to cu…
BridgeBio Pharma has delivered a strong share price gain over the past three years, yet its current checks suggest the stock now looks closer to fairly valued than obviously cheap. With recent news around its ATTR-CM therapy acoramidis kee…
During these busy times, it pays to stay on top of the latest profit opportunities. And today's blog post should be a great place to start. After taking a close look at the latest data on institutional buying pressure and each company's fu…
BridgeBio Pharma, Inc. - This voluntary agreement expands access for Medicaid patients to BridgeBio's currently marketed medicine and lowers drug costs for Americans without jeopardizing innovation and sustainability in rare diseases - Bri…
(Bloomberg) -- The Trump administration has struck new drug pricing agreements with nine biotech and pharmaceutical companies including UCB SA, Bridgebio Pharma Inc. and Sun Pharmaceutical Industries Ltd. Most Read from Bloomberg Nvidia to…
BridgeBio Pharma, Inc. - Acoramidis is the first therapy shown to potentially reverse cardiac structural disease progression and functional decline through 42 months based on CMR imaging, with up to half of patients showing clinically mean…
[Alnylam Pharmaceuticals, Inc.] hapabapa/iStock Editorial via Getty Images AstraZeneca (AZN [https://seekingalpha.com/symbol/AZN]) on Friday released full data from a failed Phase 3 trial for its RNA-targeting silencer Wainua, developed wi…
The Trump administration is expected to announce a series of drug pricing deals with several mid-size biotech companies as early as Monday, adding to similar agreements reached with Big Pharma since late last year, Bloomberg News reported…
BridgeBio Pharma, Inc. - The ASCEND-ATTR study builds on the Phase 3 ATTRibute-CM CMR substudy results previously shared here, which indicated treatment with acoramidis may improve cardiac structure and function with evidence of amyloid re…
BridgeBio Pharma BBIO entered the second half of 2026 with Attruby doing most of the commercial heavy lifting. Second-quarter revenues rose 120% year over year and topped the Zacks Consensus Estimate, but the company still posted a wider-t…